108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
IL17A 和 IL36R 双重阻断治疗难治性化脓性汗腺炎：一例报告
Authors Yu Y, Li J, Liu H , Sun Y , Zhang F
Received 13 August 2025
Accepted for publication 29 September 2025
Published 3 October 2025 Volume 2025:19 Pages 581—584
DOI https://doi.org/10.2147/BTT.S558500
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Shein-Chung Chow
Yueqian Yu,1,2 Jianke Li,1,2 Hong Liu,1,2 Yonghu Sun,1,2 Furen Zhang1,2
1Dermatology Hospital of Shandong First Medical University, Jinan, Shandong, 250022, People’s Republic of China; 2Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, 250022, People’s Republic of China
Correspondence: Yonghu Sun, Dermatology Hospital of Shandong First Medical University & Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, 27397 Jingshi Road, Jinan, Shandong, 250022, People’s Republic of China, Tel +86-0531-87298801, Fax +86-0531-87984734, Email suohandong@126.com
Abstract: Hidradenitis suppurativa (HS), a chronic inflammatory disorder affecting approximately 1% of the global population, remains challenging to treat due to the limited efficacy of single biologics (TNFa/IL-17/IL-36 inhibitors) against draining tunnels (dTs). A man with refractory HS (Hurley stage III) was treated with recibokibart (anti-IL36R antibody) and secukinumab (anti-IL17A antibody). Disease severity was assessed using previously validated clinical outcome measures and ultrasonography. Rapid clinical improvement was observed in this patient. HiSCR50 was achieved at week 2, and HiSCR100 (complete resolution of inflammatory nodules and abscesses without new dTs) by week 10. The pain score decreased from 8 to 2, and the exudation resolved. The size of the tunnels in the four intertrigonal areas was significantly reduced, as assessed by ultrasound. This case highlights the synergistic potential of dual IL-17/IL-36 blockade, particularly for dTs, and offers a novel therapeutic strategy for treating severe HS.
Keywords: Hidradenitis suppurativa, IL-17A, IL-36R
1Dermatology Hospital of Shandong First Medical University, Jinan, Shandong, 250022, People’s Republic of China; 2Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, 250022, People’s Republic of China
Correspondence: Yonghu Sun, Dermatology Hospital of Shandong First Medical University & Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, 27397 Jingshi Road, Jinan, Shandong, 250022, People’s Republic of China, Tel +86-0531-87298801, Fax +86-0531-87984734, Email suohandong@126.com
Abstract: Hidradenitis suppurativa (HS), a chronic inflammatory disorder affecting approximately 1% of the global population, remains challenging to treat due to the limited efficacy of single biologics (TNFa/IL-17/IL-36 inhibitors) against draining tunnels (dTs). A man with refractory HS (Hurley stage III) was treated with recibokibart (anti-IL36R antibody) and secukinumab (anti-IL17A antibody). Disease severity was assessed using previously validated clinical outcome measures and ultrasonography. Rapid clinical improvement was observed in this patient. HiSCR50 was achieved at week 2, and HiSCR100 (complete resolution of inflammatory nodules and abscesses without new dTs) by week 10. The pain score decreased from 8 to 2, and the exudation resolved. The size of the tunnels in the four intertrigonal areas was significantly reduced, as assessed by ultrasound. This case highlights the synergistic potential of dual IL-17/IL-36 blockade, particularly for dTs, and offers a novel therapeutic strategy for treating severe HS.
Keywords: Hidradenitis suppurativa, IL-17A, IL-36R